OKYO PHARMA LTD SP.ADR/65 Cash Flow-to-Debt Ratio
OKYO PHARMA LTD SP.ADR/65 cash flow-to-debt ratio. OKYO PHARMA LTD SP.ADR/65 (OK10) has a Cash Flow-to-Debt Ratio of -0.20x as of March 2025, meaning its operating cash flow of €-1.81 Million could theoretically repay 0% of its total liabilities (€9.23 Million) in one year. See OKYO PHARMA LTD SP.ADR/65 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of OKYO PHARMA LTD SP.ADR/65 (2022–2025)
Cash flow-to-debt ratio of OKYO PHARMA LTD SP.ADR/65 from 2022 to 2025. Historical debt coverage capacity for OKYO PHARMA LTD SP.ADR/65 across 4 annual periods. Also explore OKYO PHARMA LTD SP.ADR/65 (OK10) equity growth momentum to track the company's year-over-year net asset growth rate.
OKYO PHARMA LTD SP.ADR/65 Cash Flow-to-Debt Ratio by Year (2022–2025)
OKYO PHARMA LTD SP.ADR/65 cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for OKYO PHARMA LTD SP.ADR/65. For the full cash flow conversion analysis, see OKYO PHARMA LTD SP.ADR/65 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.20x | €-1.81 Million | €9.23 Million | ▲ +84.7% |
| 2024 | -1.28x | €-9.49 Million | €7.42 Million | ▼ -20.6% |
| 2023 | -1.06x | €-7.70 Million | €7.26 Million | ▲ +73.8% |
| 2022 | -4.04x | €-5.47 Million | €1.35 Million | — |